What You Should Know:
– CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their diabetes.
– In addition to improved clinical outcomes, health plans and risk-bearing providers can also realize savings of up to $2,200 per patient per year from this increase in CGM adherence.
PropheSee Model Boosts Adherence Rates in High-Risk Patient Cohorts by 50%
CCS has observed a remarkable 50% increase in adherence rates among high-risk patient cohorts following the deployment of its new predictive model, PropheSee. This significant improvement is attributed to tech-enabled, personalized interventions based on risk classification, combined with the timely delivery of patient-specific information and insights that support long-term therapy adherence.
CCS leverages a comprehensive dataset that includes decades of proprietary patient behavior data, offering a far more holistic view of an individual’s health and well-being compared to traditional claims data, which is often delayed and incomplete. Additionally, the integration of patient-level Social Determinants of Health (SDOH) data provides a more complete understanding of each patient. This enables healthcare organizations to proactively identify those most at risk of discontinuing therapy.
As a leading chronic care management company, CCS provides clinical solutions and home-delivered medical supplies for individuals with chronic conditions, particularly diabetes. The company collaborates with health plans, providers, and employers to streamline the patient journey. CCS integrates medical devices, pharmaceuticals, and clinical education and coaching services into a seamless platform, ensuring a cohesive and effective healthcare experience.
“CCS can now proactively identify if a member is at a higher risk of falling off therapy, and then take action based on individual specific insights to best support them in maintaining adherence,” said Richard Mackey, CTO at CCS. “The launch of PropheSee reinforces our commitment at CCS to deliver a smarter, more personalized approach to keeping people on therapy – resulting in healthier members and lower cost for the healthcare ecosystem.”
